Samarium oxide as a radiotracer to evaluate the in vivo biodistribution of PLGA nanoparticles

Show simple item record

dc.contributor.author Mandiwana, Vusani
dc.contributor.author Kalombo, Lonji
dc.contributor.author Venter, Kobus
dc.contributor.author Sathekge, Mike Machaba
dc.contributor.author Grobler, Anne
dc.contributor.author Zeevaart, Jan Rijn
dc.date.accessioned 2017-02-14T07:57:44Z
dc.date.available 2017-02-14T07:57:44Z
dc.date.issued 2015-09
dc.description.abstract Developing nanoparticulate delivery systems that will allow easy movement and localization of a drug to the target tissue and provide more controlled release of the drug in vivo is a challenge in nanomedicine. The aim of this study was to evaluate the biodistribution of poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles containing samarium-153 oxide ([153Sm]Sm2O3) in vivo to prove that orally administered nanoparticles alter the biodistribution of a drug. These were then activated in a nuclear reactor to produce radioactive 153Sm-loaded-PLGA nanoparticles. The nanoparticles were characterized for size, zeta potential, and morphology. The nanoparticles were orally and intravenously (IV) administered to rats in order to trace their uptake through imaging and biodistribution studies. The 153Sm-loaded-PLGA nanoparticles had an average size of 281 ± 6.3 nm and a PDI average of 0.22. The zeta potential ranged between 5 and 20 mV. The [153Sm]Sm2O3 loaded PLGA nanoparticles, orally administered were distributed to most organs at low levels, indicating that there was absorption of nanoparticles. While the IV injected [153Sm]Sm2O3-loaded PLGA nanoparticles exhibited the highest localization of nanoparticles in the spleen (8.63 %ID/g) and liver (3.07 %ID/g), confirming that nanoparticles are rapidly removed from the blood by the RES, leading to rapid uptake in the liver and spleen. From the biodistribution data obtained, it is clear that polymeric nanoscale delivery systems would be suitable for improving permeability and thus the bioavailability of therapeutic compounds. en_ZA
dc.description.department Nuclear Medicine en_ZA
dc.description.librarian hb2017 en_ZA
dc.description.uri http://link.springer.com/journal/11051 en_ZA
dc.identifier.citation Mandiwana, V., Kalombo, L., Venter, K., Sathekge, M., Grobler, A. & Zeevaart, J.R. Samarium oxide as a radiotracer to evaluate the in vivo biodistribution of PLGA nanoparticles. Journal of Nanoparticle Research (2015) 17: 375. doi:10.1007/s11051-015-3182-3. en_ZA
dc.identifier.issn 1388-0764 (print)
dc.identifier.issn 1572-896X (online)
dc.identifier.other 10.1007/s11051-015-3182-3
dc.identifier.uri http://hdl.handle.net/2263/59014
dc.language.iso en en_ZA
dc.publisher Springer en_ZA
dc.rights © Springer Science+Business Media Dordrecht 2015. The original publication is available at : http://link.springer.com/journal/11051. en_ZA
dc.subject Biodistribution en_ZA
dc.subject In vivo en_ZA
dc.subject Imaging en_ZA
dc.subject Nanoparticles en_ZA
dc.subject Samarium oxide en_ZA
dc.subject Drug delivery en_ZA
dc.subject Nanomedicine en_ZA
dc.subject Poly(D,L-lactide-co-glycolide) (PLGA) en_ZA
dc.title Samarium oxide as a radiotracer to evaluate the in vivo biodistribution of PLGA nanoparticles en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record